BSD 500

BSD 2000

BSD 2000 Video

	An FDA Approved Product
	A powerful tool in treating progressive and recurrent cancer
	Ideal for use in combination with HDR brachytherapy
	Portable, space-efficient and easy to operate
	High resolution touch screen display for use in treatment planning, setup and monitoring
	500 Watts of microwave energy and up to 8 channels
	Advanced new microwave generation system allowing an operator to electronically direct and shape the pattern of hyperthermia treatments to the shape and size of the tumor
	Typical treatment sites include: breast, prostate, head and neck, colorectal, melanoma, carcinomas and sarcomas.
	Approved for treatment of tumors through superficial and interstitial techniques
	Available for use with interstitial antennae and superficial applicators on the same equipment
	Superficial hyperthermia is used to non-invasively treat cancerous tumors located within a few centimeters of the surface of the body, such as melanoma and recurrent breast cancer.
	Interstitial hyperthermia is used in treating prostate cancer, breast cancer, head and neck cancer and a variety of other cancers.

We pioneered a medical solution for enlarged prostate to improve the quality of life for millions of men...

ISO & CE certified
ISO 9001:2000
ISO 13485:2003

Our technology has applications for treatment of other diseases and medical conditions.

Our systems kill cancer cells and boost the effectiveness of other cancer therapies incuding surgery, chemotherapy and radiation.

System Overview
The BSD 500 interstitial microwave hyperthermia system is equipped with a 915 MHz power generator. The solid state generator has 8 channels (BSD 500-8i) which can be independently adjusted in phase and amplitude. The 8 channel generator feeds into a 3 way power splitter. Therefore up to 24 applicators can be connected.

Closed-end Catheters
16 gauge (1.1 mm) I.D. closed-ended radiopaque, non-pyrogenic, sterile catheters are furnished to use for insertion of the temperature probes into a tissue mass.

Operating System Software
Windows XP operating system
Hyperthermia treatment procedures
Treatment Recall
Temperature monitoring procedures
User and diagnostic programs
Automatic calculation of real time thermal dose
Interstitial pre-treatment planning

Computer
CD Drive
512 MB RAM
Windows based operating system
Monitor is Touch Screen but mouse and keyboard may be added at operator's preference
All functions controlled via Touch Screen monitor

Solid State Microwave Power Generator
	Output frequency of 915 ± 13 MHz (ISM frequency, requires no RF shielded enclosure)
	8 independent channels of 0 to 60 watts
	Forward and reflected powers of all 8 channels are monitored, controlled and displayed by the computer
	All 8 channels are driven by a single power signal. The power balance of the channel is software controlled using the touch screen monitor
	Can be switched to a single output of 0 to 400 watts under computer control. The 8 signals representing forward power are summed and displayed as total power

System Calibration and Cooling Module
Integrated thermal well
Standard NBS traceable temperature probe, accurate within 0.05 °C
Constant volume water supply
Bolus temperature controller with a temperature range of 5 °C to 45 °C

Equipment Rack
	Free standing and mobile on swivel-locking casters
	Operator station and component support arm are mounted on top of the equipment rack
	Microwave generator and computer assembly are mounted in the rack
	Rotating temperature and interstitial antennae interface mounted on top of chassis
	Equipment size is 60 x 60 x 90 cm to table top. Approximately 150 cm to top of the monitor.

Advanced Microwave Interstitial System
	24 MA-251 semi-rigid interstitial applicators to be inserted into 16 gauge (1.1 mm I.D.) closed tip or 16 gauge radiation implant catheters. Heating pattern is ellipsoidal and approximately 4.5 cm in length along the applicator shaft, with heating to the applicator tip.
	Different heating patterns can be created by using symmetrical synchronous or non-synchronous arrays of up to 24 applicators, with independent control of up to 8 channels split 3 ways.
	Applicator length is 30 cm with a 92 cm extension cable that allows clinical flexibility in patient positioning.
	Applicator diameter is 1.1 mm; typical of a 16 gauge closed end catheter commonly used in radiation implants.

Power Requirements
115 - 230 VAC +/- 10%, 50 - 60 Hz
Current consumption <15 amps

Temperature Probes
	Four probes are provided with the basic system, interface accepts up to 8 probes.
	A typical treatment set-up would utilize 12 to 15 ports for the microwave interstitial applicators and 1 to 4 ports for connections to the temperature probes.
	Temperatures are displayed in accuracy of ± 0.1 °C.
	Inherently stable thermistor type probes with non-metallic leads. Calibration typically required only once a month.
	Non-perturbed by microwave fields.
	Diameter approximately 1.1 mm for 33 cm (13 in.) from the sensor.
	Length approximately 2.1 m (7ft).
	Leakage currents guaranteed to be less than 15 micro amps for any type of failure.

Variable length heating coils create optimal
heat distribution

Optional superficial applicators are available to treat a wide range of tumor sizes and locations.

Precise control of 24 interstitial applicators

Touch screen technology
allows greater control

…13 consecutive patients with symptomatic, locally advance, previously irradiated and hormone refractory prostate cancer were treated with further irradiation and external hyperthermia. All patients had complete resolution of symptoms lasting for 12-24 months.
J. Kalapurakal, et.al., Int. J.Radiation Oncology, Biol. Phys., vol. 57, No 3, pp 654-664, 2003

The combined result of the five trials has demonstrated the efficacy of hyperthermia as an adjunct to radiotherapy for treatment of recurrent breast cancer.
C.C.Vernon, et.al., Int. J. Radiation Oncology, Biol.Phys., Vol. 35, No. 4, pp 731-744, 1996

BREAST CANCER
“…The overall CR rate for RT alone was 41% and for the combined (HT+RT) treatment arm was 59%.”
Int.J.Radiation Oncology Biol.Phys. vol. 35 No 4, 1996

PELVIC TUMORS-CERVIX
“3-year overall survival rate was 27% in the radiotherapy group and 51% in the radiotherapy plus hyperthermia group.”
The Lancet vol. 355 April 1, 2000

MELANOMA
“Invariate analysis showed a beneficial effect of hyperthermia (radiation alone 28% vs combined treatment 46%)…Adjuvant hyperthermia significantly improved local tumor control when applied in association with radiation in treatment of malignant melanoma.”
The Lancet vol. 345 March, 1995

PROSTATE CANCER
“…patients with symptomatic, locally advance, previously irradiated and hormone refractory prostate cancer were treated with further irradiation and external hyperthermia. All patients had complete resolution of symptoms lasting for 12-24 months.”
The British Journal of Radiology 74 (2001) 745-751

HEAD AND NECK
“Complete response occurred in 24 patients (89%), partial in 3 (11%)…The results of this study indicate that outpatient interstitial thermoradiotherapy is convenient, safe and efficacious in treating human neoplasms.”
Cancer 1996;77:2363-70

Click for Clinical Reports